BRIEF-Immunovaccine names Frederic Ors permanent CEO

Tue Aug 9, 2016 6:16pm EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Aug 9 (Reuters) - Immunovaccine Inc

* Immunovaccine provides corporate update and announces second quarter 2016 financial results

* Says securing $8 million in a bought deal private placement financing

* Immunovaccine Inc says appointing Medicago CEO and president Andy Sheldon as board chairman, and CTI LSF's Shermaine Tilley as a board director

* Says "ceasing our Pharmathene collaboration related to anthrax"

* Says naming Frederic Ors permanent chief executive officer

* Says initiating a search for a chief medical officer

* Qtrly net loss and comprehensive loss of $1.4 million Source text for Eikon: Further company coverage: